Loading
Invitae Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Feb 2016.
Invitae Corp: what insiders have been doing
This page follows insider dealings at Invitae Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Invitae Corp in twelve months, the latest record being from 21 December 2023.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
100
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€6M
43 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$444.5M
Net income-US$2.7B-601.6% margin
Last declaration on 21 December 2023
Declarations100 total
17,404 shares@ US$0.6480.6% of flowCommon StockSEC:0000950170-23-072402:0
17,404 shares@ US$0.6480.8% of flowCommon StockSEC:0000950170-23-072400:0
850,000 shares0Common StockSEC:0000950170-23-063939:0
229,500 shares0Common StockSEC:0000950170-23-054454:0
850,000 shares0Common StockSEC:0000950170-23-051251:0
850,000 shares0Common StockSEC:0000950170-23-049737:0
7,086 shares@ US$1.3770.5% of flowCommon StockSEC:0000950170-23-028349:0
7,079 shares@ US$1.3770.7% of flowCommon StockSEC:0000950170-23-028347:0
45,432 shares@ US$1.19932.3% of flowCommon StockSEC:0000899243-23-013237:0
26,476 shares@ US$1.19932.3% of flowCommon StockSEC:0000899243-23-013230:0
21,559 shares@ US$1.19932.0% of flowCommon StockSEC:0000899243-23-013232:0
26,476 shares@ US$1.19931.6% of flowCommon StockSEC:0000899243-23-013235:0
70,422 shares0Common StockSEC:0000899243-23-011937:0
70,422 shares0Common StockSEC:0000899243-23-011935:0
70,422 shares0Common StockSEC:0000899243-23-011927:0
70,422 shares0Common StockSEC:0000899243-23-011931:0
70,422 shares0Common StockSEC:0000899243-23-011936:0
70,422 shares0Common StockSEC:0000899243-23-011930:0
70,422 shares0Common StockSEC:0000899243-23-011928:0
1,200,000 shares0Common StockSEC:0000899243-23-010813:0
300,000 shares0Common StockSEC:0000899243-23-010807:0
120,000 shares0Common StockSEC:0000899243-23-010812:0
155,000 shares0Common StockSEC:0000899243-23-010814:0
25 of 100 declarations
About Invitae Corp
Invitae Corp. is a U.S.-based medical genetics and molecular diagnostics company that built its business around clinical genetic testing. Historically listed in the United States on the NYSE under the ticker NVTA, the company developed a platform aimed at making genetic information more accessible and actionable for physicians, hospitals, laboratories, and patients. Invitae was founded in 2010 and established its headquarters in San Francisco, California, placing it in one of the most active biotech hubs in the United States. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Invitae?utm_source=openai))
Operationally, Invitae focused on a broad menu of medical genetics services. Its core offering included hereditary cancer testing, reproductive health testing, pediatric genetics, neurology, and rare-disease panels, along with interpretation and reporting tools designed to support clinical decision-making. The company’s strategy was to expand the number of genes and disease areas covered by its tests, and its 2016 panel expansion showed a deliberate push to deepen clinical utility across a wider set of indications. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/2016/default.aspx?utm_source=openai))
Read moreShow less
From a competitive standpoint, Invitae positioned itself as a scaled specialist in the genetic testing market, competing with other genomics-focused diagnostics companies and diversified clinical laboratories. Its value proposition was built on breadth of assay coverage, a digitally enabled testing workflow, and an ambition to become a more comprehensive platform for medical genetics. In 2020, the company announced a planned combination with ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology, underlining how central oncology and precision medicine were to its strategic narrative. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/press-release-details/2020/Invitae-and-ArcherDX-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology/default.aspx?utm_source=openai))
The most important recent development for investors is the company’s sharp operational reset. After significant financial stress, Invitae sold assets in 2024, and Labcorp completed the acquisition of select Invitae assets on August 5, 2024. As a result, the name “NVTA” should now be viewed through the lens of restructuring, asset sales, and a much smaller footprint than the one Invitae had during its growth phase. For investors in French-speaking markets, this is no longer a straightforward growth stock story; it is a U.S. healthcare situation marked by restructuring and asset monetization. The company was a U.S. issuer with exposure to the NYSE/NASDAQ universe, but its economic profile has materially changed. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/press-release-details/2024/Labcorp-Finalizes-Acquisition-of-Select-Assets-of-Invitae-2024-x_frzgmkDn/default.aspx?utm_source=openai))
In short, Invitae became a recognizable name in U.S. medical genetics through hereditary cancer and molecular diagnostic testing, but recent divestitures have transformed it from a broad-based genomics growth company into a much more complex, event-driven equity case. ([ir.invitae.com](https://ir.invitae.com/news-and-events/press-releases/press-release-details/2024/Labcorp-Finalizes-Acquisition-of-Select-Assets-of-Invitae-2024-x_frzgmkDn/default.aspx?utm_source=openai))
